Xerion Healthcare Ltd is pleased to announce that it has been awarded a grant to conduct research into the use of its nanoparticle products for the treatment of pancreatic cancers.
Innovate UK, the UK’s innovation agency, will grant Xerion £240425 under its Biomedical Catalyst – Early Stage scheme to co-fund the project which aims to make a substantial contribution to the treatment of these tumours. Pancreatic cancers are the most deadly of the common tumour types with a five year survival rate of only 3%. Over 9400 cases are diagnosed in the UK per year, the majority at advanced stages where surgery is impossible and chemotherapy ineffective. Xerion Healthcare Ltd will use enhanced versions of their first generation product to enable effective radiotherapy treatment of this devastating disease.